Correlation between choline kinase alpha expression and
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 10 2023
17 10 2023
Historique:
received:
14
07
2023
accepted:
10
10
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Choline kinase (CK) is reportedly overexpressed in various malignancies. Among its isoforms, CKα overexpression is presumably related to oncogenic change. Choline positron emission tomography (PET) is reportedly useful for detecting and evaluating therapy outcomes in malignancies. In this study, we investigated the correlation between CKα expression and
Identifiants
pubmed: 37848481
doi: 10.1038/s41598-023-44542-4
pii: 10.1038/s41598-023-44542-4
pmc: PMC10582087
doi:
Substances chimiques
Carbon Radioisotopes
0
Choline
N91BDP6H0X
Choline Kinase
EC 2.7.1.32
Radiopharmaceuticals
0
CHKA protein, human
EC 2.7.1.32
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17620Informations de copyright
© 2023. Springer Nature Limited.
Références
Ishidate, K. Choline/ethanolamine kinase from mammalian tissues. Biochim. Biophys. Acta. 1348(1–2), 70–78 (1997).
doi: 10.1016/S0005-2760(97)00118-5
pubmed: 9370318
Ramírez de Molina, A. et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 64(18), 6732–6739 (2004).
doi: 10.1158/0008-5472.CAN-04-0489
pubmed: 15374991
Ramirez de Molina, A. et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 296(3), 580–583 (2002).
doi: 10.1016/S0006-291X(02)00920-8
pubmed: 12176020
Ramírez de Molina, A. et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 21(27), 4317–4322 (2002).
doi: 10.1038/sj.onc.1205556
pubmed: 12082619
Gallego-Ortega, D. et al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 4(11), e7819 (2009).
doi: 10.1371/journal.pone.0007819
pubmed: 19915674
pmcid: 2773002
Gruber, J. et al. Balance of human choline kinase isoforms is critical for cell cycle regulation: Implications for the development of choline kinase-targeted cancer therapy. FEBS J. 279(11), 1915–1928 (2012).
doi: 10.1111/j.1742-4658.2012.08573.x
pubmed: 22429312
Gokhale, S. & Xie, P. ChoK-full of potential: Choline kinase in B cell and T cell malignancies. Pharmaceutics 13(6), 911 (2021).
doi: 10.3390/pharmaceutics13060911
pubmed: 34202989
pmcid: 8234087
Katz-Brull, R., Lavin, P. T. & Lenkinski, R. E. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 94(16), 1197–1203 (2002).
doi: 10.1093/jnci/94.16.1197
pubmed: 12189222
Nelson, S. J. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 46(2), 228–239 (2001).
doi: 10.1002/mrm.1183
pubmed: 11477625
Sharma, U. & Jagannathan, N. R. Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS). Biophys Rev. 12(5), 1163–1173 (2020).
doi: 10.1007/s12551-020-00758-6
pubmed: 32918707
pmcid: 7575675
Hara, T., Kosaka, N., Sinoura, N. & Kondo, T. PET imaging of brain tumor with [methyl- 11C] choline. J. Nucl. Med. 38(6), 842–847 (1997).
pubmed: 9189127
Nitsch, S. et al. Evaluation of prostate cancer with 11C- and 18F-choline PET/CT: Diagnosis and initial staging. J. Nucl. Med. 57(Suppl 3), 38S-42S (2016).
doi: 10.2967/jnumed.115.169748
pubmed: 27694169
Kenny, L. M. et al. Reproducibility of [11C]choline positron emission tomography and effect of trastuzumab. Clin. Cancer Res. 16(16), 4236–4245 (2010).
doi: 10.1158/1078-0432.CCR-10-0468
pubmed: 20682702
Contractor, K. B. et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin. Cancer Res. 15, 5503–5510 (2009).
doi: 10.1158/1078-0432.CCR-09-0666
pubmed: 19706823
Contractor, K. et al. Use of [11C]Choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin. Cancer Res. 17(24), 7673–7683 (2011).
doi: 10.1158/1078-0432.CCR-11-2048
pubmed: 22038995
Tateishi, U. et al. Comparative study of the value of dual tracer PET/CT in evaluating breast cancer. Cancer Sci. 103(9), 1701–1707 (2012).
doi: 10.1111/j.1349-7006.2012.02348.x
pubmed: 22632272
pmcid: 7659263
Fukukita, H. et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: Synopsis of version 1.0. Ann. Nucl. Med. 24(4), 325–334 (2010).
doi: 10.1007/s12149-010-0377-7
pubmed: 20401547
Hara, T. & Yuasa, M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl. Radiat. Isot. 50(3), 531–533 (1999).
doi: 10.1016/S0969-8043(98)00097-9
pubmed: 10070713
Elston, C. W. & Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19(5), 403–410 (1991).
doi: 10.1111/j.1365-2559.1991.tb00229.x
pubmed: 1757079
McCarty, K. S. et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 146(8 Suppl), 4244s–4248s (1986).
Grech-Sollars, M. et al. Imaging and tissue biomarkers of choline metabolism in diffuse adult glioma: 18F-fluoromethylcholine PET/CT, magnetic resonance spectroscopy, and choline kinase α. Cancers (Basel) 11(12), 1969 (2019).
doi: 10.3390/cancers11121969
pubmed: 31817833
Huang, Z., Rui, J., Li, X., Meng, X. & Liu, Q. Use of
doi: 10.3892/mmr.2015.3200
pubmed: 25591716
pmcid: 4368073
Kwee, S. A., Hernandez, B., Chan, O. & Wong, L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: Association with survival. PLoS One 7(10), e46591 (2012).
doi: 10.1371/journal.pone.0046591
pubmed: 23071593
pmcid: 3465336
Ramírez de Molina, A. et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: A retrospective study. Lancet Oncol. 8(10), 889–897 (2007).
doi: 10.1016/S1470-2045(07)70279-6
pubmed: 17851129
Kitajima, K. et al. Prognostic value of 18F-FDG PET/CT prior to breast cancer treatment. Comparison with magnetic resonance spectroscopy and diffusion weighted imaging. Hell. J. Nucl. Med. 22(1), 25–35 (2019).
pubmed: 30843007
Diao, W., Tian, F. & Jia, Z. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. Eur. J. Radiol. 105, 1–7 (2018).
doi: 10.1016/j.ejrad.2018.05.014
pubmed: 30017264
Peterson, L. M. et al. Prospective study of serial 18F-FDG PET and 18F-Fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer. J. Nucl. Med. 59(12), 1823–1830 (2018).
doi: 10.2967/jnumed.118.211102
pubmed: 29748233
pmcid: 6278903
Mirlacher, M. et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod. Pathol. 17(11), 1414–1420 (2004).
doi: 10.1038/modpathol.3800208
pubmed: 15205686
Fergenbaum, J. H. et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol. Biomark. Prev. 13(4), 667–672 (2004).
doi: 10.1158/1055-9965.667.13.4